Publications by authors named "David A Tice"

Claim this Profile
C
Controlling CAR-T cell activity and specificity with synthetic SparX adapters.
Justin P Edwards, Jeffrey S Swers, Janine M Buonato, Liubov Zaritskaya, C Jenny Mu, David A Tice

Mol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Krista Kinneer, Philipp Wortmann, Zachary A Cooper, Niall J Dickinson, Luke Masterson, David A Tice

Clin Cancer Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.
Janine M Buonato, Justin P Edwards, Liubov Zaritskaya, Alexandra R Witter, Ankit Gupta, David A Tice

Mol Cancer Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.
Vera Grinkevitch, Mark Wappett, Nyree Crawford, Stacey Price, Andrea Lees, David A Tice

Mol Cancer Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
Shenlan Mao, Raghothama Chaerkady, Wen Yu, Gina D'Angelo, Andrew Garcia, David A Tice

Mol Cancer Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Steven Coats, Marna Williams, Benjamin Kebble, Rakesh Dixit, Leo Tseng, David A Tice

Clin Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
Krista Kinneer, Matt Flynn, Suneetha B Thomas, John Meekin, Reena Varkey, David A Tice

Leukemia· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Yoshimi Endo Greer, Samuel F Gilbert, Brunilde Gril, Rajesh Narwal, Danielle L Peacock Brooks, David A Tice

Breast Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Therapeutic Window in -mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
Haihong Zhong, Cui Chen, Ravinder Tammali, Shannon Breen, Jing Zhang, David A Tice

Mol Cancer Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Krista Kinneer, John Meekin, Arnaud C Tiberghien, Yu-Tzu Tai, Sandrina Phipps, David A Tice

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Song Cho, Francesca Zammarchi, David G Williams, Carin E G Havenith, Noel R Monks, David A Tice

Mol Cancer Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.
Emily E Bosco, R James Christie, Rosa Carrasco, Darrin Sabol, Jiping Zha, David A Tice

Oncotarget· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
Krishna Kalyan Kolluri, Constantine Alifrangis, Neelam Kumar, Yuki Ishii, Stacey Price, David A Tice

Elife· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Jay Harper, Christopher Lloyd, Nazzareno Dimasi, Dorin Toader, Rose Marwood, David A Tice

Mol Cancer Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.
Samuel A Kerk, Kelsey A Finkel, Alexander T Pearson, Kristy A Warner, Zhaocheng Zhang, David A Tice

Clin Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.
Kelsey A Finkel, Kristy A Warner, Samuel Kerk, Carol R Bradford, Scott A McLean, David A Tice

Neoplasia· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Zhan Xiao, Rosa A Carrasco, Kevin Schifferli, Krista Kinneer, Ravinder Tammali, David A Tice

Mol Cancer Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.
Haihong Zhong, April Davis, Maria Ouzounova, Rosa A Carrasco, Cui Chen, David A Tice

Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.
Jonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, Dave Stewart, Linda Xu, David A Tice

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors.
Nabendu Pore, Sanjoo Jalla, Zheng Liu, Brandon Higgs, Claudio Sorio, David A Tice

Neoplasia· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.
Stéphanie Sungalee, Emilie Mamessier, Ester Morgado, Emilie Grégoire, Philip Z Brohawn, David A Tice

J Clin Invest· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis.
Jeffery S Swers, Luba Grinberg, Lin Wang, Hui Feng, Kristen Lekstrom, David A Tice

Mol Cancer Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
Zhan Xiao, Rosa Carrasco, Krista Kinneer, Darrin Sabol, Bahija Jallal, David A Tice

Cancer Biol Ther· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Nai-Ying Yang, Carlos Fernandez, Melanie Richter, Zhan Xiao, Fatima Valencia, David A Tice

Cell Signal· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma.
Stergios J Moschos, Cindy A Sander, Wenjun Wang, Shelley L Reppert, Laura M Drogowski, David A Tice

J Immunother· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis